Skip to main content
. 2020 Oct 10;132:110848. doi: 10.1016/j.biopha.2020.110848

Fig. 4.

Fig. 4

HCQ prevented DC functions by TLR9. (A) Purified DCs were obtained from PBMC of a healthy donor and stimulated by serum of healthy controls (n = 6) and RA patients (DAS28-ESR＞5.1, n = 6), respectively. The result showed that the level of TLR9 in RA patient serum stimulated DCs was enhanced and this effect was inhibited by HCQ. ##P < 0.01: DCs stimulated by RA patient serum vs DCs stimulated by healthy control serum, * P < 0.05: HCQ + DCs stimulated by RA patient serum vs DCs stimulated by RA patient serum. (B) In CIA mice, the level of TLR9 in LN DCs of CIA mice was elevated when compared to healthy control and this effect was inhibited by HCQ. ##P < 0.01: CIA model vs healthy control mice. ** P < 0.01: HCQ-treated mice vs vehicle-treated mice. (C) In BMDCs, the level of TLR9 in CpG-activated BMDCs was up-regulated and this was inhibited by HCQ. #P < 0.05: CpG-activated BMDCs vs CpG-inactivated BMDCs (Ctrl); ** P <0.01: HCQ + BMDCs stimulated by CpG compared to BMDCs stimulated by CpG.